Building Durability in Rare Disease Care With PANTHERx Rare

Sponsored by PANTHERx Rare

Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven by targeted incentives, tax breaks, and a more streamlined FDA approval pathway. Nagji covers the operational realities that set rare disease therapies apart, including cold chain logistics, weight-based titration regimens, and the intensive patient interactions required before a single prescription is even filled. Learn why launch marks the beginning of a therapy's journey rather than its conclusion, and why ongoing work is necessary for payer access and long-term adherence.